2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients

Efficacy of the neurokinin-1 receptor antagonist rolapitant in preventing nausea and vomiting in patients receiving carboplatin-based chemotherapy

(2016) Paul J. Hesketh et al.   CANCER

Anticipatory Nausea, Risk Factors, and Its Impact on Chemotherapy-Induced Nausea and Vomiting: Results From the Pan European Emesis Registry Study

(2016) Alexander Molassiotis et al.   JOURNAL OF PAIN AND SYMPTOM MANAGEMENT

Efficacy and safety of fosaprepitant for the prevention of nausea and emesis during 5 weeks of chemoradiotherapy for cervical cancer (the GAND-emesis study): a multinational, randomised, placebo-controlled, double-blind, phase 3 trial

(2016) Christina H Ruhlmann et al.   LANCET ONCOLOGY

Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: results of a randomized, double-blind phase III trial

(2015) C. Weinstein et al.   ANNALS OF ONCOLOGY

Recent developments in the prevention of chemotherapy-induced nausea and vomiting (CINV): a comprehensive review

(2015) K. Jordan et al.   ANNALS OF ONCOLOGY

Aprepitant versus metoclopramide, both combined with dexamethasone, for the prevention of cisplatin-induced delayed emesis: a randomized, double-blind study

(2015) F. Roila et al.   ANNALS OF ONCOLOGY

Combination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy (SENRI trial): A multicentre, randomised, controlled phase 3 trial

(2015) Junichi Nishimura et al.   EUROPEAN JOURNAL OF CANCER

Efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting with a moderately emetogenic chemotherapy regimen: a multicenter, placebo-controlled, double-blind, randomized study in patients with gynecologic cancer receiving paclitaxel and carboplatin

(2015) Hideaki Yahata et al.   International Journal of Clinical Oncology

Double-Blind, Placebo-Controlled, Randomized Trial of Octreotide in Malignant Bowel Obstruction

(2015) David C. Currow et al.   JOURNAL OF PAIN AND SYMPTOM MANAGEMENT

Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled, double-blind, phase 3 trial

(2015) Lee S Schwartzberg et al.   LANCET ONCOLOGY

Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials

(2015) Bernardo L Rapoport et al.   LANCET ONCOLOGY

Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in children: a randomised, double-blind, phase 3 trial

(2015) Hyoung Jin Kang et al.   LANCET ONCOLOGY

Efficacy and safety of oral palonosetron compared with IV palonosetron administered with dexamethasone for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with solid tumors receiving cisplatin-based highly emetogenic chemotherapy (HEC)

(2015) Meinolf Karthaus et al.   SUPPORTIVE CARE IN CANCER

Efficacy and safety of olanzapine combined with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy in gynecological cancer: KCOG-G1301 phase II trial

(2015) Masakazu Abe et al.   SUPPORTIVE CARE IN CANCER

Aprepitant as an add-on therapy in children receiving highly emetogenic chemotherapy: a randomized, double-blind, placebo-controlled trial

(2015) Sameer Bakhshi et al.   SUPPORTIVE CARE IN CANCER

Study of rolapitant, a novel, long-acting, NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) due to highly emetogenic chemotherapy (HEC)

(2015) Bernardo Rapoport et al.   SUPPORTIVE CARE IN CANCER

Randomized clinical trial comparing octreotide and scopolamine butylbromide in symptom control of patients with inoperable bowel obstruction due to advanced ovarian cancer

(2015) Xingang Peng et al.   World Journal of Surgical Oncology

Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study

(2014) P. J. Hesketh et al.   ANNALS OF ONCOLOGY

A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy

(2014) M. Aapro et al.   ANNALS OF ONCOLOGY

5-Hydroxytryptamine3receptor antagonists and cardiac side effects

(2014) Louise Brygger et al.   Expert Opinion On Drug Safety

Aprepitant, Granisetron, and Dexamethasone for Prevention of Chemotherapy-Induced Nausea and Vomiting After High-Dose Melphalan in Autologous Transplantation for Multiple Myeloma: Results of a Randomized, Placebo-Controlled Phase III Trial

(2014) Thomas Schmitt et al.   JOURNAL OF CLINICAL ONCOLOGY

Aprepitant in patients with advanced non-small-cell lung cancer receiving carboplatin-based chemotherapy

(2014) Yasuhiro Ito et al.   LUNG CANCER

Guideline for the prevention and treatment of anticipatory nausea and vomiting due to chemotherapy in pediatric cancer patients

(2014) L. Lee Dupuis et al.   PEDIATRIC BLOOD & CANCER

Incidence and predictors of anticipatory nausea and vomiting in Asia Pacific clinical practice—a longitudinal analysis

(2014) Alexandre Chan et al.   SUPPORTIVE CARE IN CANCER

Aprepitant for the control of delayed nausea and vomiting associated with the use of high-dose melphalan for autologous peripheral blood stem cell transplants in patients with multiple myeloma: a phase II study

(2014) Thomas Bechtel et al.   SUPPORTIVE CARE IN CANCER

Antiemetic efficacy and safety of a combination of palonosetron, aprepitant, and dexamethasone in patients with testicular germ cell tumor receiving 5-day cisplatin-based combination chemotherapy

(2014) Shota Hamada et al.   SUPPORTIVE CARE IN CANCER

Efficacy and safety of palonosetron for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis of randomized controlled trials

(2014) Marko Popovic et al.   SUPPORTIVE CARE IN CANCER

Can Granisetron Injection Used as Primary Prophylaxis Improve the Control of Nausea and Vomiting with Low-Emetogenic Chemotherapy?

(2013) Chan Huan Keat et al.   Asian Pacific Journal of Cancer Prevention

A randomised, placebo-controlled, double-blind study of aprepitant in nondrinking women younger than 70 years receiving moderately emetogenic chemotherapy

(2013) M Tanioka et al.   BRITISH JOURNAL OF CANCER

Anticipatory nausea and vomiting due to chemotherapy

(2013) Charles Kamen et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Aprepitant Versus Dexamethasone for Preventing Chemotherapy-Induced Delayed Emesis in Patients With Breast Cancer: A Randomized Double-Blind Study

(2013) Fausto Roila et al.   JOURNAL OF CLINICAL ONCOLOGY

Evaluation of Risk Factors Predicting Chemotherapy-Related Nausea and Vomiting: Results From a European Prospective Observational Study

(2013) Alexander Molassiotis et al.   JOURNAL OF PAIN AND SYMPTOM MANAGEMENT

Efficacy of oral palonosetron compared to intravenous palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: a phase 3 trial

(2013) Ralph Boccia et al.   SUPPORTIVE CARE IN CANCER

Aprepitant triple therapy for the prevention of chemotherapy-induced nausea and vomiting following high-dose cisplatin in Chinese patients: a randomized, double-blind, placebo-controlled phase III trial

(2013) Zhihuang Hu et al.   SUPPORTIVE CARE IN CANCER

The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy

(2013) Rudolph M. Navari et al.   SUPPORTIVE CARE IN CANCER

Efficacy and safety of single-dose fosaprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving high-dose cisplatin: a multicentre, randomised, double-blind, placebo-controlled phase 3 trial

(2012) H. Saito et al.   ANNALS OF ONCOLOGY

Prevention of Nausea and Vomiting Associated with Stem Cell Transplant: Results of a Prospective, Randomized Trial of Aprepitant Used with Highly Emetogenic Preparative Regimens

(2012) Patrick J. Stiff et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Equivalent Dynamic Human Brain NK1-Receptor Occupancy Following Single-Dose i.v. Fosaprepitant vs. Oral Aprepitant as Assessed by PET Imaging

(2012) K Van Laere et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Randomized, Double-Blind, Placebo-Controlled, Phase III Cross-Over Study Evaluating the Oral Neurokinin-1 Antagonist Aprepitant in Combination With a 5HT3 Receptor Antagonist and Dexamethasone in Patients With Germ Cell Tumors Receiving 5-Day Cisplatin Combination Chemotherapy Regimens: A Hoosier Oncology Group Study

(2012) Costantine Albany et al.   JOURNAL OF CLINICAL ONCOLOGY

Symptomatic Treatment With Lanreotide Microparticles in Inoperable Bowel Obstruction Resulting From Peritoneal Carcinomatosis: A Randomized, Double-Blind, Placebo-Controlled Phase III Study

(2012) Pascale Mariani et al.   JOURNAL OF CLINICAL ONCOLOGY

Results of a 7-day aprepitant schedule for the prevention of nausea and vomiting in 5-day cisplatin-based germ cell tumor chemotherapy

(2012) I. N. Olver et al.   SUPPORTIVE CARE IN CANCER

Single-Dose Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated With Cisplatin Therapy: Randomized, Double-Blind Study Protocol—EASE

(2011) Steven Grunberg et al.   JOURNAL OF CLINICAL ONCOLOGY

Management of opioid-induced nausea and vomiting in cancer patients: systematic review and evidence-based recommendations

(2011) Eivor A Laugsand et al.   PALLIATIVE MEDICINE

Incidence of delayed nausea and vomiting in patients with colorectal cancer receiving irinotecan-based chemotherapy

(2011) Paul J. Hesketh et al.   SUPPORTIVE CARE IN CANCER

Single-dose intravenous casopitant in combination with ondansetron and dexamethasone for the prevention of oxaliplatin-induced nausea and vomiting: a multicenter, randomized, double-blind, active-controlled, two arm, parallel group study

(2011) Paul J. Hesketh et al.   SUPPORTIVE CARE IN CANCER

A Triple-Drug Combination to Prevent Nausea and Vomiting Following BEAM Chemotherapy Before Autologous Hematopoietic Stem Cell Transplantation

(2011) W. Pielichowski et al.   TRANSPLANTATION PROCEEDINGS

Prophylaxis of Radiation-Induced Nausea and Vomiting Using 5-Hydroxytryptamine-3 Serotonin Receptor Antagonists: A Systematic Review of Randomized Trials

(2010) Nadia Salvo et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Efficacy and tolerability of transdermal granisetron for the control of chemotherapy-induced nausea and vomiting associated with moderately and highly emetogenic multi-day chemotherapy: a randomized, double-blind, phase III study

(2010) Ralph V. Boccia et al.   SUPPORTIVE CARE IN CANCER

Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial

(2009) Mitsue Saito et al.   LANCET ONCOLOGY

A prospective observational trial on emesis in radiotherapy: Analysis of 1020 patients recruited in 45 Italian radiation oncology centres

(2009) Ernesto Maranzano et al.   RADIOTHERAPY AND ONCOLOGY

Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study

(2009) Bernardo L. Rapoport et al.   SUPPORTIVE CARE IN CANCER

One third of patients with radiotherapy-induced nausea consider their antiemetic treatment insufficient

(2008) Anna Enblom et al.   SUPPORTIVE CARE IN CANCER